Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
AssigneeSynchroneuron, LLC
InventorBarry S. Fogel
Life of this patent
Estimating the term…
Abstract
The present invention describes a novel treatment for movement disorders, including tardive dyskinesia and tardive dystonia, and focal dystonias not due to neuroleptics, including blepharospasm, Meige syndrome, and occupational dystonias. The treatment of the present invention utilizes agents that act as NMDA-type glutamate receptor antagonists The invention also involves the use of an ion channel blocking agent to augment the therapeutic action of the drug treatments described. A particularly preferred ion channel blocking agent is magnesium.
Claims52
A method of treating a human subject for involuntary movement symptoms of movement disorders selected from the group consisting of dystonia and tardive dyskinesia comprising:
- administering to said human subject an effective amount of a NMDA-receptor antagonist selected from the group consisting of memantine and derivatives and congeners thereof that have similar pharmacodynamic effects in respect to NMDA-type glutamate neurotransmission.
A method for treating involuntary movement symptoms of a human patient for involuntary movement symptoms of movement disorders selected from the group consisting of dystonia and tardive dyskinesia comprising the steps of:
- selecting a first pharmacologically active agent that acts as a NMDA-type glutamate receptor antagonist;
- and
- administering an effective amount of said first agent to a human patient with a movement disorder.
A method of treating involuntary movement symptoms of movement disorders comprising:
- augmenting the therapeutic effects of memantine in human patients with movement disorders by administering to said patient an effective dose of magnesium ion.
A method of treating involuntary movement symptoms of movement disorders comprising:
- augmenting the therapeutic effects of dextromethorphan in human patients with movement disorders by administering to said patient an effective dose of magnesium ion.
A method for treating involuntary movement symptoms of a movement disorder comprising:
- administering to a human patient in combination, a single composition at an effective dose,
- (i) an NMDA receptor antagonist;
- and
- (ii) magnesium ion.
A composition for treating movement disorders in a human subject comprising:
- one or more agents that decrease NMDA-glutamate neurotransmission;
- and
- an effective amount of magnesium ion.
A composition for the treatment of involuntary movement symptoms of movement disorders in a human subject comprising:
- (i) a effective amount of memantine
- (ii) an effective amount of an inorganic salt or chelate of magnesium.
A composition for the treatment of involuntary movement symptoms of movement disorders in a human subject comprising:
- (i) an effective amount of memantine
- (ii) an effective amount of dextromethorphan
- (ii) an effective amount of an inorganic salt or chelate of magnesium.
Dependencies are inferred from the claim text.